Superworth

CRISPR Therapeutics price to free cash flow CRSP

Market value divided by free cash flow over the last twelve months, since 2019.

Today, Nov 2, 2026
n/m
not a meaningful number
Last meaningful
15.2×
Aug 2022
7-year median
20.0×
7-year range
8.1× to 220×
Peer median
24.0×

CRISPR Therapeutics' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Aug 2022, at 15.2×.

On the days it had one over the last 7 years, its median was 20.0×, from 8.1× in May 2022 to 220× in Dec 2019.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
202215.2×8.1×15.6×
202112.5×11.5×20.7×
2020143×45.8×182×
2019200×153×220×

Against its peers

Companies in Biotechnology nearest CRISPR Therapeutics' size, closest first, today.

CompanyPrice to free cash flow
CRSPCRISPR Therapeuticsn/m
KRYSKrystal Biotech34.0×
ADMAAdma Biologics21.3×
RGENRepligen87.2×
VCELVericel33.6×
TECHBIO-TECHNE43.3×
HALOHalozyme Therapeutics18.2×
NBIXNeurocrine Biosciences17.0×
EXELExelixis14.8×
ALNYAlnylam Pharmaceuticals26.7×
INCYIncyte12.7×
Peer median24.0×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on CRISPR Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.